Answers are grounded in this paper and cite their sources.
Epigenetic editing enables programmable and heritable gene regulation without altering DNA sequence, yet existing platforms remain constrained by large size, cumbersome target design, and limited applicability. Here we engineered catalytically inactive ISDge10 and ISAam1 TnpB systems and developed highly compact RNA-guided epigenetic editors compatible with single adeno-associated virus (AAV) delivery for either transcriptional activation or repression. Activators based on these TnpBs (Dge10on and Aam1on) efficiently activated diverse endogenous genes in vitro, and AAV9-delivered Aam1on achieved robust pancreatic and duodenal homeobox 1 (Pdx1) activation in vivo. For gene repression, by screening 248 human Krüppel-associated box (KRAB) domains with verified effector activity, we identified the most potent effector domain for each TnpB system, resulting in the optimization of Dge10off and Aam1off. These epigenetic editors mediated durable transcriptional repression across multiple loci in diverse cell types. In a mouse model, single-AAV delivery of these editors efficiently suppressed vascular endothelial growth factor A (Vegfa) expression with no detectable activation of DNA damage response markers (γH2AX and p53), resulting in marked reductions in choroidal neovascularization area. Our study expands the epigenetic editing toolbox and provides a potentially safe and durable single-administration therapeutic strategy for wet age-related macular degeneration (wAMD).
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: